EA201500431A1 - Соединения боронатного эфира и его фармацевтические составы - Google Patents
Соединения боронатного эфира и его фармацевтические составыInfo
- Publication number
- EA201500431A1 EA201500431A1 EA201500431A EA201500431A EA201500431A1 EA 201500431 A1 EA201500431 A1 EA 201500431A1 EA 201500431 A EA201500431 A EA 201500431A EA 201500431 A EA201500431 A EA 201500431A EA 201500431 A1 EA201500431 A1 EA 201500431A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bononate
- compounds
- air
- pharmaceutical compositions
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Изобретение обеспечивает получение новых соединений, применимых в качестве ингибиторов протеасом. Изобретение также обеспечивает получение фармацевтически приемлемых рецептур с содержанием веществ, указанных в изобретении, а также обеспечивает методами использования данных рецептур при лечении различных заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13224408P | 2008-06-17 | 2008-06-17 | |
US21149909P | 2009-03-31 | 2009-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201500431A1 true EA201500431A1 (ru) | 2015-11-30 |
Family
ID=41061278
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500431A EA201500431A1 (ru) | 2008-06-17 | 2009-06-16 | Соединения боронатного эфира и его фармацевтические составы |
EA201170036A EA027346B1 (ru) | 2008-06-17 | 2009-06-16 | Соединения боронатного эфира и его фармацевтические составы |
EA201500432A EA201500432A1 (ru) | 2008-06-17 | 2009-06-16 | Соединения боронатного эфира и его фармацевтические составы |
EA201500430A EA030685B1 (ru) | 2008-06-17 | 2009-06-16 | Способ получения соединения боронатного эфира |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201170036A EA027346B1 (ru) | 2008-06-17 | 2009-06-16 | Соединения боронатного эфира и его фармацевтические составы |
EA201500432A EA201500432A1 (ru) | 2008-06-17 | 2009-06-16 | Соединения боронатного эфира и его фармацевтические составы |
EA201500430A EA030685B1 (ru) | 2008-06-17 | 2009-06-16 | Способ получения соединения боронатного эфира |
Country Status (38)
Country | Link |
---|---|
US (17) | US20090325903A1 (ru) |
EP (6) | EP2733147A1 (ru) |
JP (9) | JP5566380B2 (ru) |
KR (5) | KR101690571B1 (ru) |
CN (10) | CN107253975A (ru) |
AR (1) | AR072162A1 (ru) |
AU (1) | AU2009260778B2 (ru) |
BR (4) | BR122014008754A2 (ru) |
CA (2) | CA2921946C (ru) |
CL (1) | CL2010001475A1 (ru) |
CO (1) | CO6321289A2 (ru) |
CR (3) | CR11850A (ru) |
CY (1) | CY1116435T1 (ru) |
DK (2) | DK2730581T3 (ru) |
DO (1) | DOP2010000384A (ru) |
EA (4) | EA201500431A1 (ru) |
EC (2) | ECSP11010763A (ru) |
ES (2) | ES2541467T3 (ru) |
GE (2) | GEP20135847B (ru) |
HK (9) | HK1157786A1 (ru) |
HR (1) | HRP20150592T1 (ru) |
IL (3) | IL210056B (ru) |
MA (1) | MA32471B1 (ru) |
MX (4) | MX2010013642A (ru) |
MY (2) | MY155592A (ru) |
NO (1) | NO2017016I1 (ru) |
NZ (4) | NZ624122A (ru) |
PE (5) | PE20141064A1 (ru) |
PH (3) | PH12015501192A1 (ru) |
PL (1) | PL2318419T3 (ru) |
PT (2) | PT2730581T (ru) |
RS (1) | RS54020B1 (ru) |
SG (2) | SG194349A1 (ru) |
SI (1) | SI2318419T1 (ru) |
TW (3) | TWI498333B (ru) |
UA (1) | UA115131C2 (ru) |
WO (1) | WO2009154737A1 (ru) |
ZA (4) | ZA201009177B (ru) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2623113T3 (en) | 2005-11-09 | 2017-07-17 | Onyx Therapeutics Inc | Enzyme inhibition compound |
RU2450016C2 (ru) | 2006-06-19 | 2012-05-10 | Протеоликс, Инк. | Пептидные эпоксикетоны для ингибирования протеасомы |
PT2207791T (pt) | 2007-10-04 | 2016-07-12 | Onyx Therapeutics Inc | Inibidores da epoxi cetona protease de péptido cristalino e a síntese de ceto-epóxidos de aminoácidos |
EA201500431A1 (ru) * | 2008-06-17 | 2015-11-30 | Милленниум Фармасьютикалз, Инк. | Соединения боронатного эфира и его фармацевтические составы |
KR101023994B1 (ko) | 2008-08-28 | 2011-03-28 | 한국생산기술연구원 | 디지털 밴드용 커넥터, 리셉터클 및 커넥터 조립체 |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
KR20110073584A (ko) | 2008-10-21 | 2011-06-29 | 오닉스 세라퓨틱스, 인크. | 펩티드 에폭시케톤과의 병용 요법 |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
RU2012146101A (ru) | 2010-03-31 | 2014-05-10 | Милленниум Фармасьютикалз, Инк. | Производные 1-амино-2-циклопропилэтилбороновой кислоты |
EP2624818B1 (en) | 2010-10-05 | 2017-04-05 | Fresenius Kabi USA, LLC | Bortezomib formulations stabilised with boric acid |
CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
JP5944986B2 (ja) | 2011-06-22 | 2016-07-05 | セファロン、インク. | プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013071142A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
EP2776586B1 (en) | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
US9732101B2 (en) | 2012-01-18 | 2017-08-15 | Wisconsin Alumni Research Foundation | Bioreversible boronates for delivery of molecules into cells |
US9234048B2 (en) | 2012-01-18 | 2016-01-12 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
CN104204797B (zh) * | 2012-01-24 | 2017-05-31 | 米伦纽姆医药公司 | 治疗癌症的方法 |
EP2812338A4 (en) | 2012-01-24 | 2015-09-23 | Millennium Pharm Inc | METHOD FOR THE TREATMENT OF NASOPHARYNGEAL CANCER |
AU2013227219A1 (en) * | 2012-03-02 | 2014-10-23 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
CA2784240C (en) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
ITMI20121394A1 (it) * | 2012-08-06 | 2014-02-07 | Chemi Spa | Esteri di bortezomib e loro formulazioni |
EP3008212A4 (en) * | 2013-06-10 | 2017-05-24 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
JP6165986B2 (ja) * | 2013-08-23 | 2017-07-19 | シントン・ビー.ブイ.Synthon B.V. | ボルテゾミブを含む医薬組成物 |
BR112016007237A2 (pt) | 2013-10-03 | 2017-09-12 | Millennium Pharm Inc | método para a profilaxia ou tratamento do lúpus eritematoso sistêmico e/ou nefrite lúpica |
US10167311B2 (en) | 2014-02-03 | 2019-01-01 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
WO2015151775A1 (ja) * | 2014-03-31 | 2015-10-08 | 富士フイルム株式会社 | 水分解用光電極、水分解装置 |
AU2015264272A1 (en) | 2014-05-20 | 2016-11-24 | Millennium Pharmaceuticals, Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
EP3808349B1 (en) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
US9738664B2 (en) | 2014-10-29 | 2017-08-22 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of HIV protease |
EP3031811A1 (en) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Malic acid esters of bortezomib |
MA41505A (fr) * | 2015-02-11 | 2017-12-19 | Millennium Pharm Inc | Nouvelle forme cristalline d'un inhibiteur de protéasome |
MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
CZ2015233A3 (cs) | 2015-04-03 | 2016-10-12 | Zentiva, K.S. | Způsob přípravy Ixazomib citrátu |
CZ2015253A3 (cs) | 2015-04-15 | 2016-10-26 | Zentiva, K.S. | Nové formy Ixazomib citrátu |
CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
WO2016205790A2 (en) * | 2015-06-19 | 2016-12-22 | Hanlin Scientific, Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
EP3120837A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Verfahren zur herstellung einer bortezomibester-lösung |
EP3120836A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Gebrauchsfertige bortezomib-lösung |
CA2998830A1 (en) * | 2015-09-16 | 2017-03-23 | Mylan Laboratories Limited | Polymorphs of ixazomib citrate and processes for the preparation thereof |
CN106608883A (zh) * | 2015-10-21 | 2017-05-03 | 北京大学 | 蛋白酶体抑制剂mln9708的合成方法 |
JP6875410B2 (ja) | 2015-11-04 | 2021-05-26 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 多発性骨髄腫を有する患者の識別方法、評価方法、及び治療方法 |
CN106986884A (zh) * | 2016-01-20 | 2017-07-28 | 成都贝斯凯瑞生物科技有限公司 | 一种高效的高纯度含硼化合物制备方法 |
CN105622658B (zh) * | 2016-03-18 | 2018-06-19 | 中国药科大学 | 非肽类蛋白酶体抑制剂、其药物组合物、制备方法和应用 |
WO2017163190A1 (en) * | 2016-03-23 | 2017-09-28 | Dr. Reddy’S Laboratories Limited | Amorphous ixazomib citrate and solid dispersion thereof |
CN107224569A (zh) * | 2016-03-26 | 2017-10-03 | 复旦大学 | 一种硼替佐米水溶性药用组合物及其制备方法和用途 |
CZ2016204A3 (cs) | 2016-04-08 | 2017-11-01 | Zentiva, K.S. | Formulace Ixazomib citrátu formy 3 |
EP3471734B1 (en) | 2016-06-21 | 2020-11-18 | Teva Pharmaceuticals International GmbH | Solid state forms of ixazomib citrate |
WO2018019196A1 (zh) * | 2016-07-25 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的硼酸化合物及包含该化合物的药物组合物及其用途 |
JP2019524780A (ja) * | 2016-08-04 | 2019-09-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | プロテアソーム阻害剤及び抗cd30抗体の組み合わせ |
TW201831191A (zh) * | 2017-01-23 | 2018-09-01 | 大陸商成都奥璟生物科技有限公司 | 一種新的硼酸衍生物及其藥物組合物 |
WO2018160717A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
WO2018158697A1 (en) | 2017-03-03 | 2018-09-07 | Fresenius Kabi Oncology Limited | A process for the preparation of ixazomib citrate |
WO2018173071A1 (en) * | 2017-03-20 | 2018-09-27 | Msn Laboratories Private Limited, R&D Center | Novel crystalline forms of ixazomib citrate and its process for preparation thereof |
CN106916177B (zh) * | 2017-03-23 | 2019-04-23 | 南京陵瑞医药科技有限公司 | 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途 |
CN108794516A (zh) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | 硼酸和硼酸酯类化合物及其制备方法和用途 |
CN108794520B (zh) * | 2017-05-02 | 2020-07-24 | 北京大学 | 包括埃沙佐米在内的硼酸柠檬酸酯类化合物的合成方法 |
WO2019020099A1 (zh) * | 2017-07-28 | 2019-01-31 | 成都地奥九泓制药厂 | 一种硼酸酯化合物、其合成方法及其用途 |
PL3672977T3 (pl) | 2017-08-24 | 2022-09-26 | Merck Patent Gmbh | Pochodne kwasu boronowego |
US20200199159A1 (en) | 2017-08-25 | 2020-06-25 | Synthon B.V. | Process for making ixazomib or intermediates therefor |
CN111065641A (zh) * | 2017-09-02 | 2020-04-24 | 太阳制药工业有限公司 | 柠檬酸伊沙佐米的制备方法 |
CN111108125A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
WO2019109802A1 (zh) * | 2017-12-05 | 2019-06-13 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的硼酸酯化合物的制备方法及其晶型 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US10118937B1 (en) | 2018-01-03 | 2018-11-06 | Scinopharm Taiwan, Ltd. | Process for preparing ixazomib citrate and intermediates therefor |
CN110041353A (zh) * | 2018-01-16 | 2019-07-23 | 成都译山生物科技有限公司 | 一种新的硼酸水杨酸酯类衍生物及其药物组合物 |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
CN110540547A (zh) * | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
EP3826723B1 (en) | 2018-07-26 | 2023-10-18 | Merck Patent GmbH | Boronic acid derivatives |
CN115772188A (zh) | 2018-08-02 | 2023-03-10 | 正大天晴药业集团股份有限公司 | 氮杂环丁烷衍生物的硼酸酯 |
CN115403603A (zh) | 2018-09-14 | 2022-11-29 | 成都奥璟生物科技有限公司 | 一种硼酸酯类药物及其用途 |
CN110357787A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 依沙佐米合成工艺研究 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
WO2024006337A1 (en) | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Cyclic boronic esters and their uses |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US449082A (en) * | 1891-03-24 | milbeadt | ||
US2160413A (en) | 1935-04-16 | 1939-05-30 | Schering Ag | Polyiodo derivatives of acylamino acids and their salts and a method of making the same |
NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
JPS6197352A (ja) * | 1984-10-17 | 1986-05-15 | Dai Ichi Kogyo Seiyaku Co Ltd | 安定性に優れた組成物 |
JPS6233170A (ja) | 1985-08-07 | 1987-02-13 | Tokuyama Soda Co Ltd | 環状ポリエ−テル化合物 |
JPH0813759B2 (ja) | 1986-09-01 | 1996-02-14 | 富士写真フイルム株式会社 | アルコキシベンゼン誘導体の製造方法 |
JP2512303B2 (ja) | 1987-03-20 | 1996-07-03 | 呉羽化学工業株式会社 | 2−オキサゾリン−4,5−ジオンのフエニルヒドラゾン誘導体 |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) * | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5159060A (en) * | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
ES2098484T3 (es) * | 1992-08-14 | 1997-05-01 | Procter & Gamble | Detergentes liquidos que contienen un acido alfa-amino-boronico. |
US5935944A (en) * | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
US5492900A (en) * | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
US6060462A (en) * | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
FR2712602B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
JP3403009B2 (ja) * | 1996-07-12 | 2003-05-06 | キヤノン株式会社 | 可動部材の変位と気泡成長を伴う液体吐出方法、該吐出方法に用いられる液体吐出ヘッド、ヘッドカートリッジ及びこれらを用いた液体吐出装置 |
US5834487A (en) | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
IL131410A0 (en) | 1997-02-15 | 2001-01-28 | Proscript Inc | Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab |
CA2304622A1 (en) | 1997-09-25 | 1999-04-01 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases |
US20010012854A1 (en) | 1997-12-16 | 2001-08-09 | Robert Siman | Multicatalytic protease inhibitors for use as anti-tumor agents |
US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
WO2000024392A1 (fr) | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteur de la formation de beta-amyloide |
US6169076B1 (en) * | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
US6121149A (en) * | 1999-04-22 | 2000-09-19 | Advanced Micro Devices, Inc. | Optimized trench/via profile for damascene filling |
KR100307027B1 (ko) | 1999-06-17 | 2001-11-01 | 서평원 | 액정 표시장치 및 이것을 이용한 이동 통신 단말기의 표시장치 |
AU5920400A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Cell-based assay systems for examining hcv ns3 protease activity |
SE0100714D0 (sv) | 2000-07-13 | 2001-02-28 | Ap Biotech Ab | Reaction vessel and method for distributing fluid in such a vessel |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
JP2002145848A (ja) * | 2000-11-10 | 2002-05-22 | Kyorin Pharmaceut Co Ltd | アルケニルアミノ酸誘導体及びその製造法 |
EP1217000A1 (en) * | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
ES2571219T3 (es) * | 2001-01-25 | 2016-05-24 | The United States Of America Represented By The Secretary Dept Of Health And Human Services | Formulación de compuestos de ácido borónico |
US6933290B2 (en) | 2001-05-30 | 2005-08-23 | Novartis Ag | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives |
DE10131283A1 (de) | 2001-06-28 | 2003-01-09 | Philips Corp Intellectual Pty | Phased Array Antenne |
WO2003033506A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
JP4412586B2 (ja) | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
WO2003105860A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
EP1396270B1 (en) | 2002-09-09 | 2006-05-10 | Trigen Limited | Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
MY162518A (en) * | 2003-08-14 | 2017-06-15 | Cephalon Inc | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
ME01975B (me) | 2004-03-30 | 2015-05-20 | Millennium Pharm Inc | Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline |
SG185963A1 (en) | 2004-05-10 | 2012-12-28 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
WO2006008660A2 (en) | 2004-07-20 | 2006-01-26 | Affinium Pharmaceuticals, Inc. | Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) |
TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
CN101120006A (zh) * | 2005-02-11 | 2008-02-06 | 赛福伦公司 | 蛋白酶体抑制剂及其使用方法 |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
MX2007013499A (es) | 2005-04-29 | 2008-01-24 | Kosan Biosciences Inc | Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma. |
MX2008000318A (es) | 2005-07-05 | 2008-03-11 | Tufts College | Inhibidores de la proteina alfa de activacion del fibroblasto. |
RU2008127486A (ru) * | 2005-12-08 | 2010-01-20 | Милленниум Фармасьютикалз, Инк. (Us) | Бициклические соединения с ингибиторной активностью в отношении киназы |
US20090304631A1 (en) | 2006-01-27 | 2009-12-10 | David Alan Campbell | Hepatitis c serine protease inhibitors and uses therefor |
EP1988083B1 (en) | 2006-02-03 | 2014-04-02 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
CL2007002499A1 (es) * | 2006-08-30 | 2008-03-14 | Phenomix Corp | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. |
WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
EP2178888B1 (en) * | 2007-08-06 | 2012-07-04 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
US7442830B1 (en) * | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
ITMI20072397A1 (it) | 2007-12-20 | 2009-06-21 | Gambro Lundia Ab | Apparecchiatura medicale per il trattamento extracorporeo |
EA201500431A1 (ru) * | 2008-06-17 | 2015-11-30 | Милленниум Фармасьютикалз, Инк. | Соединения боронатного эфира и его фармацевтические составы |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
RU2012146101A (ru) | 2010-03-31 | 2014-05-10 | Милленниум Фармасьютикалз, Инк. | Производные 1-амино-2-циклопропилэтилбороновой кислоты |
BR112013026094A2 (pt) | 2011-04-29 | 2016-12-27 | Ericsson Telefon Ab L M | controle descentralizado de redução de interferência em um sistema de comunicação sem fio |
JP5724951B2 (ja) | 2012-06-11 | 2015-05-27 | 日立金属株式会社 | ネットワーク管理装置 |
JP6357023B2 (ja) | 2014-06-06 | 2018-07-11 | 任天堂株式会社 | 情報処理プログラム、情報処理装置、情報処理装置の制御方法および情報処理システム |
-
2009
- 2009-06-16 EA EA201500431A patent/EA201500431A1/ru unknown
- 2009-06-16 WO PCT/US2009/003602 patent/WO2009154737A1/en active Application Filing
- 2009-06-16 CN CN201710333805.1A patent/CN107253975A/zh active Pending
- 2009-06-16 BR BR122014008754A patent/BR122014008754A2/pt not_active Application Discontinuation
- 2009-06-16 CA CA2921946A patent/CA2921946C/en active Active
- 2009-06-16 MX MX2010013642A patent/MX2010013642A/es active IP Right Grant
- 2009-06-16 NZ NZ624122A patent/NZ624122A/en unknown
- 2009-06-16 ES ES09767050.9T patent/ES2541467T3/es active Active
- 2009-06-16 RS RS20150366A patent/RS54020B1/en unknown
- 2009-06-16 MY MYPI2010005940A patent/MY155592A/en unknown
- 2009-06-16 NZ NZ624121A patent/NZ624121A/en not_active IP Right Cessation
- 2009-06-16 UA UAA201403777A patent/UA115131C2/uk unknown
- 2009-06-16 KR KR1020147019854A patent/KR101690571B1/ko active IP Right Grant
- 2009-06-16 BR BR122014008750A patent/BR122014008750A2/pt not_active Application Discontinuation
- 2009-06-16 SG SG2013069851A patent/SG194349A1/en unknown
- 2009-06-16 MY MYPI2014003632A patent/MY171021A/en unknown
- 2009-06-16 CN CN201710292950.XA patent/CN107253966A/zh active Pending
- 2009-06-16 CN CN201310349472.3A patent/CN103497232A/zh active Pending
- 2009-06-16 PT PT131914145T patent/PT2730581T/pt unknown
- 2009-06-16 KR KR1020117001181A patent/KR101691093B1/ko active IP Right Grant
- 2009-06-16 KR KR1020147019858A patent/KR101704694B1/ko active IP Right Grant
- 2009-06-16 BR BR122014008753A patent/BR122014008753A2/pt not_active Application Discontinuation
- 2009-06-16 CN CN201310349247XA patent/CN103450241A/zh active Pending
- 2009-06-16 CN CN2013103491814A patent/CN103467565A/zh active Pending
- 2009-06-16 CN CN2009801230135A patent/CN102066386A/zh active Pending
- 2009-06-16 KR KR1020177013867A patent/KR101860743B1/ko active IP Right Grant
- 2009-06-16 AU AU2009260778A patent/AU2009260778B2/en active Active
- 2009-06-16 NZ NZ624123A patent/NZ624123A/en unknown
- 2009-06-16 EP EP13191413.7A patent/EP2733147A1/en not_active Withdrawn
- 2009-06-16 CN CN201710264997.5A patent/CN107266480A/zh active Pending
- 2009-06-16 CN CN2013103488135A patent/CN103435638A/zh active Pending
- 2009-06-16 CA CA2727862A patent/CA2727862C/en active Active
- 2009-06-16 NZ NZ603236A patent/NZ603236A/en unknown
- 2009-06-16 EP EP09767050.9A patent/EP2318419B1/en active Active
- 2009-06-16 EA EA201170036A patent/EA027346B1/ru not_active IP Right Cessation
- 2009-06-16 EP EP13191414.5A patent/EP2730581B1/en not_active Revoked
- 2009-06-16 EP EP20130191412 patent/EP2730580A1/en not_active Withdrawn
- 2009-06-16 PT PT97670509T patent/PT2318419E/pt unknown
- 2009-06-16 ES ES13191414.5T patent/ES2585114T3/es active Active
- 2009-06-16 DK DK13191414.5T patent/DK2730581T3/en active
- 2009-06-16 JP JP2011514598A patent/JP5566380B2/ja active Active
- 2009-06-16 KR KR1020147019860A patent/KR101741142B1/ko active IP Right Grant
- 2009-06-16 CN CN201310349618.4A patent/CN103497210A/zh active Pending
- 2009-06-16 EP EP13191409.5A patent/EP2730579A1/en not_active Withdrawn
- 2009-06-16 EA EA201500432A patent/EA201500432A1/ru unknown
- 2009-06-16 BR BRPI0915300A patent/BRPI0915300C1/pt active IP Right Grant
- 2009-06-16 PL PL09767050T patent/PL2318419T3/pl unknown
- 2009-06-16 GE GEAP2009012060 patent/GEP20135847B/en unknown
- 2009-06-16 CN CN201710312608.1A patent/CN107266482A/zh active Pending
- 2009-06-16 DK DK09767050.9T patent/DK2318419T3/en active
- 2009-06-16 MX MX2013010325A patent/MX349769B/es unknown
- 2009-06-16 EP EP19150417.4A patent/EP3536693A1/en active Pending
- 2009-06-16 SI SI200931201T patent/SI2318419T1/sl unknown
- 2009-06-16 US US12/485,344 patent/US20090325903A1/en not_active Abandoned
- 2009-06-16 GE GEAP200912730A patent/GEP201706703B/en unknown
- 2009-06-16 EA EA201500430A patent/EA030685B1/ru not_active IP Right Cessation
- 2009-06-16 MX MX2017014406A patent/MX358222B/es unknown
- 2009-06-16 SG SG10201701524XA patent/SG10201701524XA/en unknown
- 2009-06-16 MX MX2013010326A patent/MX340186B/es unknown
- 2009-06-17 TW TW098120303A patent/TWI498333B/zh active
- 2009-06-17 PE PE2014000150A patent/PE20141064A1/es not_active Application Discontinuation
- 2009-06-17 PE PE2014000151A patent/PE20141078A1/es not_active Application Discontinuation
- 2009-06-17 TW TW103118480A patent/TWI543985B/zh active
- 2009-06-17 AR ARP090102187A patent/AR072162A1/es active IP Right Grant
- 2009-06-17 TW TW103118482A patent/TWI542351B/zh not_active IP Right Cessation
- 2009-06-17 PE PE2009000877A patent/PE20100256A1/es active IP Right Grant
- 2009-06-17 PE PE2014000152A patent/PE20141076A1/es not_active Application Discontinuation
- 2009-06-17 PE PE2014000153A patent/PE20141065A1/es not_active Application Discontinuation
-
2010
- 2010-12-10 DO DO2010000384A patent/DOP2010000384A/es unknown
- 2010-12-16 CR CR11850A patent/CR11850A/es unknown
- 2010-12-16 IL IL210056A patent/IL210056B/en active IP Right Grant
- 2010-12-17 CL CL2010001475A patent/CL2010001475A1/es unknown
- 2010-12-21 ZA ZA2010/09177A patent/ZA201009177B/en unknown
- 2010-12-23 CO CO10161489A patent/CO6321289A2/es active IP Right Grant
-
2011
- 2011-01-13 MA MA33514A patent/MA32471B1/fr unknown
- 2011-01-17 EC EC2011010763A patent/ECSP11010763A/es unknown
- 2011-11-07 HK HK11111993.1A patent/HK1157786A1/xx unknown
- 2011-11-07 HK HK14111508.6A patent/HK1198252A1/xx unknown
- 2011-11-07 HK HK14111716.4A patent/HK1198254A1/xx unknown
- 2011-11-07 HK HK14111509.5A patent/HK1198253A1/xx unknown
- 2011-11-07 HK HK14111510.2A patent/HK1199260A1/zh not_active IP Right Cessation
- 2011-12-20 ZA ZA2011/09368A patent/ZA201109368B/en unknown
-
2012
- 2012-11-02 US US13/667,164 patent/US8859504B2/en active Active
-
2013
- 2013-06-25 ZA ZA2013/04728A patent/ZA201304728B/en unknown
-
2014
- 2014-05-14 EC ECSP14010763 patent/ECSP14010763A/es unknown
- 2014-05-19 JP JP2014103398A patent/JP2014169317A/ja not_active Withdrawn
- 2014-05-19 JP JP2014103396A patent/JP6110813B2/ja active Active
- 2014-05-19 JP JP2014103397A patent/JP5926319B2/ja active Active
- 2014-05-19 JP JP2014103395A patent/JP6010066B2/ja active Active
- 2014-08-01 US US14/449,328 patent/US9175018B2/en active Active
- 2014-08-01 US US14/449,275 patent/US9175017B2/en active Active
- 2014-08-25 IL IL234285A patent/IL234285B/en active IP Right Grant
- 2014-08-25 IL IL234286A patent/IL234286A/en active IP Right Grant
-
2015
- 2015-05-27 PH PH12015501192A patent/PH12015501192A1/en unknown
- 2015-05-27 PH PH12015501191A patent/PH12015501191A1/en unknown
- 2015-05-27 PH PH12015501193A patent/PH12015501193A1/en unknown
- 2015-06-02 HR HRP20150592TT patent/HRP20150592T1/hr unknown
- 2015-06-08 ZA ZA2015/04133A patent/ZA201504133B/en unknown
- 2015-06-16 CY CY20151100519T patent/CY1116435T1/el unknown
- 2015-10-12 US US14/880,776 patent/US20160031913A1/en not_active Abandoned
-
2016
- 2016-01-08 CR CR20160014A patent/CR20160014A/es unknown
- 2016-01-08 CR CR20160015A patent/CR20160015A/es unknown
-
2017
- 2017-05-04 NO NO2017016C patent/NO2017016I1/no unknown
- 2017-06-30 JP JP2017128843A patent/JP2017214396A/ja not_active Withdrawn
- 2017-09-12 US US15/701,791 patent/US20180002350A1/en not_active Abandoned
-
2018
- 2018-03-22 US US15/928,139 patent/US20180208609A1/en not_active Abandoned
- 2018-03-27 HK HK18104204.4A patent/HK1244811A1/zh unknown
- 2018-03-27 HK HK18104201.7A patent/HK1244809A1/zh unknown
- 2018-03-27 HK HK18104202.6A patent/HK1244827A1/zh unknown
- 2018-03-27 HK HK18104203.5A patent/HK1244810A1/zh unknown
- 2018-10-18 US US16/163,694 patent/US20190048028A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/260,596 patent/US10526351B2/en active Active
- 2019-05-08 US US16/406,159 patent/US20190263839A1/en not_active Abandoned
- 2019-09-13 US US16/570,065 patent/US10604538B2/en active Active
- 2019-11-29 JP JP2019216272A patent/JP2020055829A/ja not_active Withdrawn
-
2020
- 2020-02-12 US US16/788,824 patent/US20200181176A1/en not_active Abandoned
- 2020-04-24 US US16/857,227 patent/US11485746B2/en active Active
- 2020-09-01 US US17/009,199 patent/US20200392164A1/en not_active Abandoned
-
2021
- 2021-03-11 US US17/198,442 patent/US20210198289A1/en not_active Abandoned
- 2021-07-01 JP JP2021109909A patent/JP2021165288A/ja not_active Withdrawn
- 2021-09-23 US US17/483,724 patent/US20220009948A1/en not_active Abandoned
-
2023
- 2023-05-03 US US18/311,290 patent/US20230265111A1/en not_active Abandoned
- 2023-09-07 JP JP2023145377A patent/JP2023158150A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201500430A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
EA201170508A1 (ru) | Производные 1-амино-2-циклобутилэтилбороновой кислоты | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
PH12014500053A1 (en) | Proteasome inhibitors | |
EA201001680A1 (ru) | Соединения бензолсульфонамидтиазола и оксазола | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
EA201101192A1 (ru) | Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов | |
EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
EA201291420A1 (ru) | Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли | |
EA200802000A1 (ru) | Фармацевтически приемлемые соли и полиморфные формы | |
EA201101703A1 (ru) | 17β-АЛКИЛ-17α-ОКСИЭСТРАТРИЕНЫ | |
EA201791835A3 (ru) | Ингибиторы протеасом | |
MY180594A (en) | Proteasome inhibitors | |
EA201990219A3 (ru) | Ингибиторы mek и способы их применения | |
UA106205C2 (ru) | Соединения боронатного эфира, фармацевтическая композиция (варианты), которая содержит их, и способ их получения (варианты) |